Efficacy of Duloxetine for VIPN (Vincristine-Induced Peripheral Neuropathy) Treatment

Efficacy of Duloxetine for VIPN (Vincristine-Induced Peripheral Neuropathy) Treatment - Efficacy of Duloxetine for VIPN

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016661

Enrollment

Registered

2015-04-01

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin lymphoma

Interventions

Duloxetine Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: have a symptom of VIPN after administration of (R-)CHOP/(R-)CVP for Non-Hodgkin lymphoma

Exclusion criteria

Exclusion criteria: have a symptom of peripheral neuropathy without administration of vincristine

Design outcomes

Primary

Measure	Time frame
Reduction of average pain after administration of duloxetine	—

Countries

Japan

Contacts

Public ContactHideaki Goto

Kobe University Hospital Department of Oncology and Hematology

hgoto@med.kobe-u.ac.jp078-382-5820

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026